22 Sep - 5 min read

TR-1: Standard form for notification of major holdings

TR-1: Standard form for notification of major holdings

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", the "Company", or the "Group")

22 September 2021

TR-1: Standard form for notification of major holdings

 NOTIFICATION OF MAJOR HOLDINGS



 1a. Identity of the issuer or the underlying issuer of
                                                                        MEDICLINIC INTERNATIONAL PLC
 existing shares to which voting rights are attached:

 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
 Non-UK issuer

 2. Reason for the notification (please mark the appropriate box or boxes with an “X”)

 An acquisition or disposal of voting rights                                                       X

 An acquisition or disposal of financial instruments

 An event changing the breakdown of voting rights

 Other (please specify):

 3. Details of person subject to the notification obligation

 Name                                                          PUBLIC INVESTMENT CORPORATION SOC LIMITED

 City and country of registered office (if applicable)         PRETORIA, SOUTH AFRICA

 4. Full name of shareholder(s) (if different from 3.)

 Name

 City and country of registered office (if applicable)

 5. Date on which the threshold was crossed or
                                                               20/09/2021
 reached:

 6. Date on which issuer notified (DD/MM/YYYY):                22/09/2021

 7. Total positions of person(s) subject to the notification obligation
                                                          % of voting rights
                               % of voting rights          through financial                                   Total number of
                               attached to shares            instruments             Total of both in %        voting rights of
                                 (total of 8. A)       (total of 8.B 1 + 8.B 2)          (8.A + 8.B)               issuer
                                                                             
                                                                                           
                                                       

Resulting situation on the
date on which threshold             10.086%.                                              10.086%.               737 243 810
was crossed or reached

Position of previous
notification (if                     9.982%.                                               9.982%.
applicable)


8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

A: Voting rights attached to shares

Class/type of                                       Number of voting rights                         % of voting rights
shares
                                                    Direct              Indirect              Direct                 Indirect
ISIN code (if possible)
                                              (Art 9 of Directive       (Art 10 of       (Art 9 of Directive     (Art 10 of Directive
                                             2004/109/EC) (DTR5.1)      Directive           2004/109/EC)            2004/109/EC)
                                                                      2004/109/EC)            (DTR5.1)               (DTR5.2.1)
                                                                       (DTR5.2.1)

Ordinary Shares
                                              74 357 880                                      10.086%.
ISIN: GB00B8HX8Z88



SUBTOTAL 8. A                                             74 357 880                                      10.086%



B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

                                                                                           Number of voting
                                                                                           rights that may be             % of
                                          Expiration     Exercise/                         acquired if the               voting
Type of financial instrument              date           Conversion Period                  instrument is                rights                                   
                                                                                           exercised/converted.
                                                                                       




                                                         SUBTOTAL 8. B 1                           NIL                     NIL

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive
2004/109/EC (DTR5.3.1.1 (b))

                                                                    Exercise/       Physical or                            % of
                                                     Expiration     Conversion      cash                Number of         voting
Type of financial instrument                         date           Period          settlement          voting rights     rights
                                                                                                    
                                                                                                          


                                                                                    SUBTOTAL
                                                                                                             NIL            NIL
                                                                                    8.B.2




9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not
control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer(xiii)

Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (xiv)      X
(please add additional rows as necessary)



                                                                         % of voting rights
                                      % of voting rights if it            through financial
                                        equals or is higher            instruments if it equals      Total of both if it equals
                                        than the notifiable             or is higher than the          or is higher than the 
    Name(xv)                                threshold                    notifiable threshold          notifiable threshold
                                                                              
                                      
                                                                                  
                                            
                                                                       
PUBLIC INVESTMENT
                                              10.086%.                                                         10.086%.
CORPORATION SOC LIMITED



10. In case of proxy voting, please identify:

Name of the proxy holder                                             N/A

The number and % of voting rights held                               N/A

The date until which the voting rights will be held                  N/A

11. Additional information

Name: REITUMETSE KAU
E-Mail: Reitumetse.Kau@pic.gov.za
TEL: 0127423747


Place of completion          PRETORIA, SOUTH AFRICA

Date of completion           22 September 2021

About Mediclinic International plc

Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983,
with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the UAE.

The Group's core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of
care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare
services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

At 30 June 2021, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health facilities, 18
day case clinics and 18 outpatient clinics. Hirslanden operated 17 hospitals and four day case clinics in
Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operations included 50 hospitals
(three of which in Namibia), five sub-acute hospitals, two mental health facilities and 12 day case clinics (four
of which operated by Intercare) across South Africa, and around 8 600 inpatient beds; and Mediclinic Middle
East operated seven hospitals, two day case clinics and 18 outpatient clinics with more than 900 inpatient
beds in the UAE. In addition, under management contracts, Mediclinic Middle East operates one hospital in
Abu Dhabi and will open a 200-bed hospital in the Kingdom of Saudi Arabia in mid-2022.

The Company's primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with
secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group
based in the United Kingdom and listed on the LSE.

For further information, please contact:

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Ben Atwell/Ciara Martin – UK

+44 (0)20 3727 1000

Sherryn Schooling – South Africa

+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com

Corporate broker: Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd

Date: 22-09-2021 05:30:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.
Information on this Website is provided for general information purposes only and is not a substitute for professional advice. ASX Information (including company announcements and prices) is delayed by at least 20 minutes. JSE Information (including company announcements and prices) is delayed by at least 15 minutes. Reliance on the information you access on or from this Website is solely at your own risk. We make no representation or warranty in relation to the future performance of the companies that appear on this Website. Investment in securities involves risk and you should obtain independent professional legal, financial, investment or company advice before acting on any of the information you access on this Website. Using, browsing or otherwise accessing this Website is subject to our Terms and Conditions and our Privacy Policy.

© 2021 Listcorp. ABN 60 166 140 307

Never miss news from Mediclinic International plc (JSE:MEI) when you join Listcorp.